Leerink downgrades Bristol Myers Squibb stock to Market Perform
Published on 10/09/2026 at 16:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Leerink Partners downgraded Bristol Myers Squibb from Outperform to Market Perform on October 5, 2026.
- Second-quarter revenue rose 5.70 percent year over year to USD 12.97 billion, while earnings per share reached USD 2.04.
- Bristol Myers Squibb stock was trading at EUR 53.16 at Lang & Schwarz on October 9, 2026, down 0.67 percent from EUR 53.52.
- Third-quarter results are scheduled for October 29, 2026, and the quarterly dividend is USD 0.63 per share.
Leerink Partners downgraded Bristol Myers Squibb stock (ISIN US1101221083) from Outperform to Market Perform on October 5, 2026, according to Fintel. The stock was trading at EUR 53.16 at Lang & Schwarz on October 9, 2026, down 0.67 percent versus the prior close of EUR 53.52.
Rating pressure meets solid earnings
The downgrade contrasts with Bristol Myers Squibb's second-quarter operating figures. MarketBeat reported that revenue rose 5.70 percent year over year to USD 12.97 billion in the second quarter of 2026, while earnings per share reached USD 2.04 against USD 1.60 expected.
The same report said Bristol Myers Squibb maintained fiscal 2026 adjusted earnings-per-share guidance of USD 6.75-7.00. The company also declared a quarterly dividend of USD 0.63 per share, equivalent to an annualized yield of 4.10 percent.
Three dated events shape the story
On July 30, 2026, Bristol Myers Squibb reported second-quarter revenue of USD 12.97 billion and earnings per share of USD 2.04, according to MarketBeat. On September 10, 2026, HSBC reiterated its Hold rating and raised its price target from USD 60.00 to USD 65.00 in the same report.
On October 5, 2026, Leerink Partners changed its rating from Outperform to Market Perform, according to Fintel. The latest rating action places greater weight on pipeline execution and the durability of growth products.
What does the portfolio shift mean?
Bristol Myers Squibb's Growth Portfolio generated USD 7.60 billion in revenue in the second quarter of 2026, up 15.00 percent from a year earlier, according to Yahoo Finance. The newer medicines accounted for nearly 60 percent of total revenue, while legacy revenue declined 4.00 percent in the same quarter.
That mix explains the conflicting signals. Revenue growth and the maintained fiscal 2026 outlook support the earnings case, but the rating downgrade highlights the need for newer therapies to offset patent pressure on established products.
Results date and dividend payment
Bristol Myers Squibb will announce third-quarter 2026 results on October 29, 2026, with an investor call at 8:00 a.m. ET, according to Bristol Myers Squibb. The quarterly dividend of USD 0.63 per share is scheduled for payment on November 2, 2026, according to MarketBeat.
Stock trades below the prior close
At Lang & Schwarz, Bristol Myers Squibb stock was trading at EUR 53.16 on October 9, 2026 at 4:40 p.m. CEST, down 0.67 percent versus the prior close of EUR 53.52 on October 8, 2026. The primary listing is on the NYSE, where the finance quote showed USD 59.37 on October 9, 2026 at 2:47 p.m. UTC, with a 52-week range of USD 42.52 to USD 68.64 and market capitalization of USD 121.3 billion.
The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.
Bristol Myers Squibb stock facts
- Company: Bristol-Myers Squibb Company
- ISIN: US1101221083
- Ticker: BMY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 9, 2026, 4:40 p.m. CEST): EUR 53.16
- Change versus prior close: minus 0.67 percent
- Prior close Lang & Schwarz (October 8, 2026): EUR 53.52
- Market capitalization: USD 121.3 billion (as of October 9, 2026)
- 52-week range: USD 42.52-68.64 (as of October 9, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Next earnings date: October 29, 2026
Market context: Market report S&P 500.
